info@auctorespublishing.com
+1-(302)-520-2644
+1-(302)-520-2644

Biologics in the Treatment of Severe Uncontrolled Asthma in Children

  1. Home
  2. Journals
  3. Journal of Thoracic Disease and Cardiothoracic Surgery
  4. Archives
Submit Guidelines

Review | DOI: https://doi.org/10.31579/2693-2156/024

Biologics in the Treatment of Severe Uncontrolled Asthma in Children

  • Nightingale Syabbalo *

* Professor of Physiology and Medicine, Nabanji Medical Centre, Lusaka, ZAMBIA.

*Corresponding Author: Nightingale Syabbalo, Professor of Physiology and Medicine, Nabanji Medical Centre, Lusaka, ZAMBIA.

Citation: Nightingale Syabbalo (2021). Biologics in the Treatment of Severe Uncontrolled Asthma in Children. J Thoracic Disease and Cardiothoracic Surgery, 2(2); DOI:10.31579/2693-2156/024

Copyright: © 2021, Nightingale Syabbalo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 04 June 2021 | Accepted: 17 June 2021 | Published: 30 June 2021

Keywords: airway remodeling; biologics; childhood asthma; interleukins; eosinophilic asthma; severe exacerbations; pathophysiology; obesity

Abstract

Asthma is the most common chronic disease in children, currently affecting about 7 million children. Severe uncontrolled asthma is rare in children with a prevalence of about 2.1% to 5%, but inflicts a disproportionate health burden. Children with severe asthma have increased risk of life threatening exacerbations, frequent hospitalization, worsening health-related quality of life, and impaired physical activity. Severe asthma in childhood is associated with long-term morbidities, such as bronchiolitis obliterans, impaired airway development, and development of chronic obstructive pulmonary disease in adulthood. Childhood asthma like adult-onset asthma, is classified into four cellular inflammatory phenotypes using induced sputum cytometry. The four phenotypes of asthma include eosinophilic asthma, neutrophilic asthma, paucigranulocytic asthma, and mixed cellularity asthma. The pathophysiological mechanisms of asthma involve airway inflammation and remodeling. Inflammatory mediators such as cytokines, chemokines, adhesion molecules, and growth factors play a key role in orchestration airway remodeling. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes, such as interleukin-5 (IL-5), IL-4, IL-13, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) play a key role in the pathogenesis of eosinophilic asthma. Whereas, the Th17 axis cytokines, including IL-17, IL-23, and IL-8 are responsible for the pathophysiology of neutrophilic asthma. The airway structural changes due to airway remodeling lead to thickening of the airway wall, narrowing of the bronchiolar lumen, airway obstruction, and decline in pulmonary function. Most of the children with asthma respond to low and medium inhaled corticosteroids, however a significant proportion still have severe asthma uncontrolled on the standard of care. The most common asthma phenotype in children is eosinophilic asthma, which responds superbly to biologic therapy. Children with severe asthma require add-on targeted interleukin antagonists (ILA), such as mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-4Rα). ILAs have been shown to ameliorate asthma symptoms, reduce moderate and severe exacerbations, and improve pulmonary function. Additionally, ILAs have been demonstrated to improve the health-related quality of life, and have steroid sparing effect.

Introduction

Asthma is a significant public health problem, affecting more than 358 million people globally [1], and is the most common chronic disease among children [3,4], affecting about 7 million children [4]. Asthma is a heterogeneous chronic airway disease with several distinct phenotypes characterized by different immunopathological pathways, clinical presentation, physiology, co-morbidities, biomarker of allergic inflammation, and response to treatment [5-10]. There are four cellular inflammatory phenotypes of asthma classified using induced sputum cytometry. The four phenotypes of asthma include eosinophilic asthma, neutrophilic asthma, paucigranulocytic asthma, and mixed cellularity asthma [7,11]. Patients with eosinophilic asthma have an eosinophil count ≥3% [12-14], whereas patients with neutrophilic asthma have elevated sputum neutrophil count between ≥61% [14,] and ≥64% [15], depending on the study. Mixed cellularity phenotype is typified by increase in both eosinophils (>3%), and neutrophils (>61% or >64%) [15]. Paucigranuocytic phenotype includes patients with very few eosinophils (<3>

Approximately 40-60% of patients with severe asthma have eosinophilic phenotype [17-21], whereas, the remaining patients have the non-eosinophilic phenotype. Eosinophilic asthma is the most common phenotype in children presenting with severe acute asthma; representing about 50% of the patients [22,23]. Paucigranulocytic asthma is most common in children and adults with stable asthma [23], however, acute severe neutrophilic asthma is most common in adult patients [22,23]. 

The pathophysiological mechanisms of asthma involve airway inflammation and remodeling. Inflammatory mediators such as cytokines, chemokines, adhesion molecules, enzymes, and growth factors play a key role in propagating airway remodeling. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes, play a key role in the pathogenesis of Th2-high eosinophilic asthma. On the other hand, the Th17 axis cytokines are responsible for the pathophysiology of Th2-low neutrophilic asthma [24].

Discussion

Most children with asthma respond to low and moderate doses of inhaled corticosteroids (ICS). However, about 5% of children have severe uncontrolled asthma despite maximal standard of care, including high dose ICS, which are associated with serious side effects. Children with severe uncontrolled asthma require add-on biological treatment, such as omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-4Rα). ILAs have been shown to ameliorate asthma symptoms, reduce moderate and severe exacerbations, and improve pulmonary function. Additionally, ILAs have been demonstrated to improve health-related quality of life, and have steroid-sparing effects [25]. This review highlights targeted treatment of severe uncontrolled asthma using the currently approved biologics for the treatment of childhood asthma.

Pathophysiology of Asthma

The pathophysiology and immunological mechanisms in the pathogenesis of childhood asthma and adult-onset asthma are basically similar. Airway inflammation and remodeling plays a key role in the pathogenesis of childhood asthma. During airway inflammation, cytokines secreted by type 2 helper (Th2) lymphocytes (CD4+), and innate lymphoid cells group 2 (ILC2), such as interleukin-5 (IL-5), IL-4, IL-13, IL-25, IL-33, and thymic stromal lymphphopoietin (TSLP) play an important role in the pathogenesis of eosinophilic asthma [26-36]. On the other hand, Th17 cytokines (IL-17, IL-17F), IL-23, and IL-8 play a pivotal role in the pathophysiology of neutrophilic asthma [24, 37-39]. However, there is some cross-talk between the Th2 and the Th17 axes in the pathogenesis of asthma [40]. Several excellent schematic diagrams on the mechanisms and characteristic pathological features of asthma immunopathology are given elsewhere [41].

Inflammation cells, such as eosinophils, mast cells, neutrophils, basophils, and structural cells including epithelial cells, fibroblasts, myofibroblasts, and airway smooth muscle (ASM) cells also secrete inflammatory cytokines, chemokines, adhesion molecules, enzymes, and growth factors which orchestrate airway remodeling. Airway remodeling is an active process which occurs early in childhood asthma [42-45], and correlates with the severity of asthma [46-48], and is associated with fatal pediatric and adolescent asthma [49]. It occurs in both eosinophilic and non-eosinophilic asthma [50].

Airway remodeling is a complex pathophysiological process involving structural changes, such as epithelial cell metaplasia and desquamation [51]; deposition of extracellular matrix proteins by fibroblasts and myofibroblasts [52-55]; thickening of the reticular basement membrane [42,52]; subepithelial fibrosis [56];  ASM cells hyperplasia and hypertrophy [57]. Additionally, airway remodeling is accompanied by submucosal glands and goblet cells hyperplasia, and mucus hypersecretion [58,59]; and angiogenesis [50,60]. The structural changes lead to thickening of the airway wall, airway narrowing, excessive bronchoconstriction, and severe, uncontrolled asthma. Table 1 summarizes the pathophysiologic mechanisms of airway remodeling in severe childhood asthma.

Table 1. Pathophysiological mechanisms of airway remodeling in severe childhood asthma

Childhood Asthma

Asthma is the most common chronic disease in childhood, affecting about 10-15% of school-age children [61]. It is most common in boys [1,62]. Severe uncontrolled asthma in children only accounts for 2 to 5% of childhood asthma [63-65], but contributes to huge costs, and utilization of health care resources [66,67]. Severe asthma is associated with significant morbidity, such as increased risk of life threatening exacerbations, frequent hospitalization, worsening health-related quality of life, and impaired physical activity [68-70]. Severe asthma in children may impair airway development and reduce maximally attained lung function, and the lung function loss may persist in adult life [62]. It is also associated with long-term morbidities, such as bronchiolitis obliterans [71]; progressive airflow limitation [70]; and development of chronic obstructive pulmonary disease in adulthood [72-75]. Furthermore, children with asthma are more susceptible to medication-related side effects, particularly with the new biologics [75]. 

Asthma in children is associated with co-morbities [76,77], such as allergic rhinitis [78,79], chronic rhinosinusitis and nasal polyps [80,81], atopic dermatitis [82,83], gastroesophageal reflux disease [84,85], obstructive sleep apnea [86,87], food allergy [88], and obesity [89,90]. Obesity is associated with decreased response to inhaled corticosteroids in overweight and obese asthmatic children [91]. Co-morbid diseases associated with asthma may make asthma control difficult, they require medical and/or surgical treatment [36].

Children with severe asthma have elevated biomarkers of Th2 eosinophilic inflammation, such as high sputum and blood eosinophil counts, high IgE levels [92-94], high fractional exhaled nitric oxide (FeNO) [95,96], and elevated serum periostin concentration [92].  Biomarkers of eosinophilic inflammation should be assessed for selection of asthmatic children for add-on treatment with biologics [96,97]. Children with persistent symptoms, and exacerbations despite correct inhaler technique and adherence should be referred to an asthma specialist with expertise in severe asthma [70].

Treatment of Severe Asthma in Children

Childhood asthma is usually controlled with low to moderate doses of inhaled corticosteroids. However, about 5% of children experience severe uncontrolled asthma despite maximal standard of care, including high dose ICS (GINA steps 4 and 5) [1]. High dose ICS have serious side effects in children including impaired growth velocity, decrease bone mineral density, and pneumonia. Children with severe uncontrolled asthma may require targeted add-on biologic treatment, which has been available for adults since the approval of omalizumab (Xolair®) on June 30, 2003. Although most of the clinical trials on biologics have been conducted in adult patients with asthma [98], biologics are very effective and safe as add-on treatment for severe eosinophilic asthma in children. Currently, there are four biologics which have been approved for add-on treatment of severe childhood asthma [99]. They include omalizumab (anti-IgE) [100,101], mepolizumab (anti-IL-5) [102,103], benralizumab (anti-IL-5Rα) [104,105], and dupilumab (anti-4Rα) [106,107]. Table 2 shows the list of the current approved biologics for the treatment of childhood asthma, and some ILAs still in development, or phased out of the clinical trials. 

Abbreviations: FDA, Food and Drug Administration; IL, interleukin; R, receptor; TSLP, thymic stromal lymphopoietin; NA, not approved for adults and children. Brodalumab, secukinumab, and risankizumab are approved for the treatment of plaque psoriasis.                                                                                              Table 2. Biologics for the treatment of asthma, their targets, and date of approval by FDA

Add-on biologics have been shown to reduce asthma symptoms, decrease moderate to severe exacerbations, and improve pulmonary function in children with severe asthma [108-114]. Additionally, biologics improve health-related quality of life, and have been used to taper or stop oral corticosteroids in patients with severe asthma [102,104,115]. The dosages of the currently approved biologics by the US Food and Drug Administration (FDA) are shown in Table 3. 

Abbreviations:     IV, intravenous; SC, subcutaneous, Q, every; wk, weeks. Note: pediatric dosages depend on body weight of child or adolescent.                                                                                     Table 3. Dosages of approved biologics by the Food and Drug Administration for the treatment of severe asthma

Children and adolescent dosages vary with age and weight of the patient, and also vary with authors.

Biologics are safe for add-on treatment of severe asthma in children. They have almost similar manageable side effects because of their immunological effects on eosinophils, and other systemic effects, such as injection site reaction, respiratory tract infection, nasopharyngitis, sinusitis, conjunctivitis, headache, arthralgia, myalgia, muscle weakness, parasitosis, and rarely anaphylaxis (Table 4) [36].

Table 4. Side-effects of biological treatment in patients with eosinophilic asthma

Eosinophils play an important role in protection against parasitic infection, including helminth infestation. Patients with pre-existing helminth infections should be treated for the infection before initiating biologic therapy. If individuals become infected whilst receiving treatment with biologics and do not respond to anti-helminth treatment, temporary discontinuation of the biologic should be considered [36].

 

Notably, some of the biologics, such as omalizumab, and dupilumab also ameliorate, and are approved for the treatment other co-morbid conditions associated with childhood asthma, such as allergic rhinitis, chronic rhinosinusitis with nasal polyps, and atopic dermatitis [116-119]. Dupilumab (Dupixent®) has been nicknamed “magic bullet’’ because it is the only biologic which has been approved by the FDA for the treatment of eosinophilic asthma [117,118]; chronic rhinosinusitis with nasal polyps [117,119]; atopic dermatitis [117,120]; and eosinophilic esophagitis [118,121,122]. 

The different immunopathological pathways of dupilumab in the treatment of asthma, allergic rhinitis, atopic dermatitis, and chronic rhinosinusitis are explained in detail elsewhere [123]. Dupixent® has been shown to be very effective and safe in the treatment of these conditions, and to improve the quality of life in children and adults [124]. 

The latest approved biologic for the treatment of severe refractory asthma is telezepelumab [125,126]. Tezepelumab is a fully human monoclonal Ig2ʎ antibody that specifically ligates TSLP by binding to its receptor TSLPR, thereby blocking human TSLP-TSLPR interaction [127]. Menziew-Gow et al. [128] have shown that tezepelumab significantly reduces the annualized asthma exacerbation in adolescent and adult asthmatics by 56% in patients with eosinophil count ≥ 300 cells.µl1, and by 41% in patients with eosinophil count < 300>

Severe, uncontrolled childhood asthma may also be treated with Complementary and Integrative Medicine (CIM), including Traditional Chinese Medicine (TCM). In order to treat severe asthma, one must understand the function of the body as a whole, in its energy level [131]. Oriental Medicine theories, such as Yin Yang and Five Elements, aligned with homeopathy may be used to achieve treatment success of severe asthma [132]. Traditional Chinese Medicine using the theory of Five Elements (wood, fire, earth, metal, and water), and Yin and Yang theory may improve the symptoms of asthma, improve whole physical, mental, and emotional picture of children with asthma [131,133,134]. TCM not only addresses the underlying condition of the patient but, also focuses on other body systems, such as the kidney (son) which may worsen lung (Qi, mother) disorders, such as asthma if not treated [131]. Many patients with chronic allergic diseases, such as asthma seek complementary and alternative therapies including Traditional Chinese Medicine. TCM is one of the oldest practice and has been used for many centuries for the treatment of asthma. There are a number of well-controlled studies on Chinese herbal formulas which have been found to be effective, safe, and have immunomodulatory effects on asthma. They include modified Mai-Men-Dong-Tang (mMMDT, five herbs), Ding-Chuan-Tang (DCT, nine herbs), and anti-asthma herbal medicine intervention (ASMI) [135].

The active ingredients in Chinese herbal medicine have multilevel effects by regulating the immunologic equilibrium mechanisms and signaling pathways, thereby regulating the progression of asthma [136]. The possible signaling pathways regulated by the ingredients of TCM herbal medicine include IL-4-IL-13-JAK-STAT-MAP kinases, adiponectin-iNOS-NF-kB, PGD2-CRTH2, PI3K/AKT, T-bet/gata-3, and Fox3-RORγt [137]. All the above signaling pathways are involved in the pathogenesis of asthma [137], and the effects of various ingredients in TCM herbal remedies are illustrated superbly by Wang and coworkers [136].

Conclusion

Asthma is the most common chronic disease in childhood, affecting about 10-15% of school-age children. Severe uncontrolled asthma in children is not common, but contributes to huge costs, and utilization of health care resources. It is associated with significant morbidity, such as increased risk of life threatening exacerbations, frequent hospitalization, and worsening health-related quality of life. Cytokines secreted by Th2 lymphocytes, and Th17 cells, such as IL-5, IL-4, IL-13, IL-25, IL-33, and TSLP; and IL-17, respectively play an important role in the pathogenesis of asthma. Most children with asthma are controlled on low to moderate dose of ICS. However, a significant proportion of children have severe asthma uncontrolled on high dose ICS. Children with severe persistent asthma require add-on treatment with biologics targeting the instigating interleukins. Interleukin antagonists have been shown to reduce asthma symptoms, decrease moderate to severe exacerbations, and improve pulmonary function in children with severe asthma. Additionally, they improve health-related quality of life, and have corticosteroids-sparing effects. Dupilumab is also effective in the treatment of childhood asthma-associated disorders, such as chronic rhinosinusitis with nasal polyps, eczema, and eosinophilic esophagitis.

References

  1. Global Initiative for Asthma. Global Strategy for Asthma management and Prevention, [updated 2021].
    View at Publisher | View at Google Scholar
  2. Asher I, Pearce N. (2014). Global burden of asthma among children. Int J Tuberc Lung Dis 2014; 18:1269-1278.
    View at Publisher | View at Google Scholar
  3. World Health Organization. Asthma. 2017. Accessed March, 7, 2017.
    View at Publisher | View at Google Scholar
  4. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey, 2016. Analysis by the American Lung Association Epidemiology and Statistics Unit using SPSS software.
    View at Publisher | View at Google Scholar
  5. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, (1999). Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-1008.
    View at Publisher | View at Google Scholar
  6. Simpson JL, Scott R, Boyle MJ, Gibson PG, (2006). Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11(1):54-61.
    View at Publisher | View at Google Scholar
  7. Anderson GP (2008). Endotypying asthma: new insights into key pathogenic mechanism in a heterogeneous disease. Lancet 2008; 372:1107-1119.
    View at Publisher | View at Google Scholar
  8. Wenzel SE (2012). Asthma phenotypes: the evolution from clinical to molecular approach. Nat Med 2012; 18:716-725.
    View at Publisher | View at Google Scholar
  9. Chung KF (2016). Asthma phenotyping: A necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016; 279:192-204.
    View at Publisher | View at Google Scholar
  10. Wang F, He XY, Baines KJ, Gunawardhana LP, Simpson JL, Gibson PG, (2011). Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J 2011; 38:567-574.
    View at Publisher | View at Google Scholar
  11. Aleman F, Lim HF, Nair P, (2016). Eosinophilic endotype of asthma. Immunol Allergy North Am 2016; 36(3):559-568.
    View at Publisher | View at Google Scholar
  12. Taylor SL, Leong LEX, Choo JM, Wesselingh S, Yang IA, Upham JW, et al. (2018). Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Imnunol 2018; 141(1):94-103.e15.
    View at Publisher | View at Google Scholar
  13. Arron JR, Choy DF, Scheerens H, Mathews JG, (2013). Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013; 10:S206-S213.
    View at Publisher | View at Google Scholar
  14. Svenningsen S, Nair P (2017). Asthma endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne) 2017; 4:158.
    View at Publisher | View at Google Scholar
  15. Thomson N (2016). Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis 2016; 10(3):211-234.
    View at Publisher | View at Google Scholar
  16. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ (1999). Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213-2214.
    View at Publisher | View at Google Scholar
  17. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE, (2004). Distinguishing severe asthma phenotypes: role of onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101-108.
    View at Publisher | View at Google Scholar
  18. Harder P, Pavord ID, Shaw DE, Barry MA, Thomas M, (2008). Cluster analysis and clinical asthma phenotypes. Am Rev Respir Crit Care Med 2008; 178:218-224.
    View at Publisher | View at Google Scholar
  19. JC de Groot, ten Brinke A, Bel EHD, (2015). Management of patients with eosinophilic asthma: a new era begins. ERJ Open Res 2015; 1(1):00024-2015.
    View at Publisher | View at Google Scholar
  20. Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community: a large electronic database analysis. Respir Med 2017; 123:131-139.
    View at Publisher | View at Google Scholar
  21. Carr TF, Zeki AA, Kraft M, (2018). Eosinophilic asthma and noneosinophilic asthma. Am J Respir Crit Care Med 2018; 197(1):22-27.
    View at Publisher | View at Google Scholar
  22. Wang F, He XY, Baines KJ, Gunawardhan LP, Simpson JL, Gibson PG, (2011). Different phenotypes in adults and children with acute asthma. Eur Respir 2011; 38:567-574.
    View at Publisher | View at Google Scholar
  23. Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E, Papaporfyriou A, Konstantellou E, et al (2016). Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma. Eur Respir J 2016; 18:PA4173; congress-2016.PA4173.
    View at Publisher | View at Google Scholar
  24. Zhu L, Ciaccio CE, Casale BT (2018). Potential new targets for drug development in severe asthma. World Allergy Org J 2018; 11:30.
    View at Publisher | View at Google Scholar
  25. Holguin F, Cardet JC, Chung KF, Diver S, Ferriera DS, Fitzpatrick A, Gaga M, Kellermeyer L, et al. Management of severe asthma. A European Respiratory Society/American Thoracic Society Guideline. Eur Respir J 2019; 26:1000588.
    View at Publisher | View at Google Scholar
  26. Doucet C, Brouty-Boyé D, Pottin-Clémenceau C, Canonica GW, Jasmin C, Azzarone B (1998). Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101:2129-2139.
    View at Publisher | View at Google Scholar
  27. Reynauld JC (2001). New insight into the role of cytokines in asthma. J Clin Pathol 2001; 54:577-589.
    View at Publisher | View at Google Scholar
  28. Wills-Karp M (2004). Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202:175-190.
    View at Publisher | View at Google Scholar
  29. Barnes PJ (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118(11):3546-3556.
    View at Publisher | View at Google Scholar
  30. Bossé Y, Thompson C, Audett K, Stankova J, Rola-Pleszczynski M (2008). Interleukin-4 and interleukin-13 enhance human bronchial muscle cell proliferation. Int Arch Allergy Immunol; 146:138-148.
    View at Publisher | View at Google Scholar
  31. Kouro T, Takatsu L (2009). IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009; 21(12):1303-1309.
    View at Publisher | View at Google Scholar
  32. Bartemes KR, Kita H (2012). Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol; 143(3):222-235.
    View at Publisher | View at Google Scholar
  33. Cayrol C, Girard JP (2014). IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy; 31:31-37.
    View at Publisher | View at Google Scholar
  34. Watson B, Gauvreau GM (2014). Thymic stromal lymphopoietin: a central regulator of allergic asthma. Expert Opin Ther Targets; 18(7):771-785.
    View at Publisher | View at Google Scholar
  35. Angkasekwinai P, Park H, Wang YH, Chang SH, Corry DB, Liu YJ, Zhu Z, Dong C (2007). Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med; 204:1509-1517.
    View at Publisher | View at Google Scholar
  36. Syabbalo N (2020). Clinical features and management of eosinophilic asthma. J Repir Dis Treat 2020; 1:105.
    View at Publisher | View at Google Scholar
  37. Nakajima H, Hirose K (2010). Role of IL-23 and Th17 cells in airway inflammation in asthma. Immune Network 2010; 10.1.
    View at Publisher | View at Google Scholar
  38. Ciprandi G, Cuppari C, Salpeitro AM, Tosca MA, Rigoli L, Grasso L, La Rosa M, et al (2012). Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int Arch Allergy Immunol; 159(2):183-186.
    View at Publisher | View at Google Scholar
  39. Syabbalo N (2020). Role of IL-17 and IL-23 in the pathogenesis of neutrophilic asthma. Int J Immunol Immunother; 7:049.
    View at Publisher | View at Google Scholar
  40. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon C, Clifford T, et al (2001). Il-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity; 15:985-995.
    View at Publisher | View at Google Scholar
  41. Busse WW. Biological treatment for severe asthma. A major advance in asthma care. Allergol Int 2019; 68:158-166.
    View at Publisher | View at Google Scholar
  42. Payne DNR, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, Jeffrey PK (2003). Early thickening of the reticular basement membrane in children with difficult asthma. Am Rev Respir Crit Care Med; 167(10:78-82.
    View at Publisher | View at Google Scholar
  43. Baena-Cagnani C, Rossi GA, Walter Canonica G (2007). Airway remodeling in children: when does it start? Curr Opin Allergy Clin Immunol; 7(2):196-200.
    View at Publisher | View at Google Scholar
  44. Bush A (2008). How early do airway inflammation and remodeling occur? Allergol Int; 57(1)11-19.
    View at Publisher | View at Google Scholar
  45. Malmström K, Pelkonen AS, Mäkelä MJ. Remodeling inflammation and airway responsiveness in early childhood asthma. Curr Opin Allergy Clin Immunol 2013; 13(2):203-210.
    View at Publisher | View at Google Scholar
  46. James A (2017). Airway remodeling in asthma: Is it fixed or variable. Am J Repir Crit Care Med 2017; 195(8).
    View at Publisher | View at Google Scholar
  47. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM (2000). Asthma. From bronchoconstriction to airway inflammation and remodeling. Am J Respir Crit Care Med 2000; 161(5):1720-1745.
    View at Publisher | View at Google Scholar
  48. Tille-Leblond I, de Blic J, Jaubert F, Wallaert B, Scheinmann G, Gosset P. Airway remodeling is correlated with obstruction in children with severe asthma. Allergy 2008; 63:533-541.
    View at Publisher | View at Google Scholar
  49. Malmström K, Lohi J, Sajantila A, Jahnsen FL, Kajosaari M, Sarna S, Mäkelä M (2017). Immunohistology and remodeling in fatal pediatric and adolescent asthma. Respir Res 2017; 18:94.
    View at Publisher | View at Google Scholar
  50. Baraldos S, Turato G, Bazzan E, Ballarin A, Damin M, Balestro E, Oliani KL, Calebrese F, Maestrelli P, et al (2011). Non-eosinophilic asthma in children: relation with airway remodeling. Eur Respir J 2011; 38:575-583.
    View at Publisher | View at Google Scholar
  51. Barbatos A, Turato G, Baraldos S, Bazzani E, Calabrese F, Panizzolo C, Zuin R, Maestrelli P, Fabbri LM (2006). Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006; 174(9):975-981.
    View at Publisher | View at Google Scholar
  52. Castro-Rodrigues JA, Saglani S, Rodriguez-Martinez CE, Oyarzun MA, Fleming L, Bush A (2008). The relationship between inflammation and remodeling in childhood asthma: a systemic review. Pediatr Pulmon 2018; 53(6):824-835.
    View at Publisher | View at Google Scholar
  53. Araujo BB, Dolhnikoff M, Silva LF, Elliot J, Lindeman JH, Ferreira DS, et al. Extracellular matrix components and regulators in the airway smooth muscle in asthma. Eur Respir J 2008; 32:61-69.
    View at Publisher | View at Google Scholar
  54. Reeves SR, Kolstad T, Lien TY, Elliot M, Ziegler SF, Wight TN, et al (2014). Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components. J Allergy Clin Immunol 2014; 134:663-570.e1.
    View at Publisher | View at Google Scholar
  55. Mostaco-Guidolin LB, Osei ET, Ullah J, Hajimohammadi S, Fouadi M, Li X, et al (2019). Fibrillar collagen organization by fibroblasts contributes to airway remodeling in asthma. Am J Respir Crit Care Med 2019; 200: 431-443.
    View at Publisher | View at Google Scholar
  56. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR (1990). Myofibroblasts and subepithial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990; 3(5):507-511.
    View at Publisher | View at Google Scholar
  57. Lezmi G, Gosset P, Deschildre A, Abou-Taam R, Mahut B, Beydon N, de Blic J (2015). Airway remodeling in children with severe recurrent wheeze. Am J Respir Crit Care Med 2015.
    View at Publisher | View at Google Scholar
  58. Jenkins HA, Cool C, Szefler SJ, Covar R, Brugman S, Gelfand EW, Spahn JD (2003). Histopathology of severe childhood asthma: a case series. Chest 2003; 124:32-41.
    View at Publisher | View at Google Scholar
  59. Fahy JV. Goblet cell and Puccini gene abnormalities in asthma. Chest 2002; 122(6 Suppl):320S-326S.
    View at Publisher | View at Google Scholar
  60. Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F (2009). Angiogenesis in asthma. Clin Exp Allergy 2009.
    View at Publisher | View at Google Scholar
  61. Bush A, Saglani S (2010). Management of severe asthma in children. Lancet 2010; 376(9743):814-825.
    View at Publisher | View at Google Scholar
  62. Dharmage SC, Perrel J, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr 2019; 7:246.
    View at Publisher | View at Google Scholar
  63. Nordlund B, Melen E, Schultz ES, Gronlund G, Kull I. Prevalence of severe childhood asthma according the WHO. Respir Med 2014; 1008:1234-1237.
    View at Publisher | View at Google Scholar
  64. Belgrave DCM, Simpson A, Semic-Jusufagic A, Murray CS, Buchan I, Pickles A, et al (2013). Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing. J Allergy Clin Immunol 2013; 132:575-583.e12.
    View at Publisher | View at Google Scholar
  65. Chung KF, Wenzel SE, Brozek JL, Bush A, Casto M, Sterk PJ, et al (2014). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-373.
    View at Publisher | View at Google Scholar
  66. Lødrup Carlsen KC, Hedlin G, Bush A, Wannergren G, de Benedictis FM, Jongste JC, et al. PSACI (Problematic Severe Asthma in Childhood Initiative) group. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37:432-440.
    View at Publisher | View at Google Scholar
  67. Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, et al (2016). Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract 2016; 4:120-129.e3.
    View at Publisher | View at Google Scholar
  68. Fleming L, Wilson N, Bush A (2007). Difficult to control asthma in children. Curr Opin Allergy Clin Immunol 2007; 7:190-195.
    View at Publisher | View at Google Scholar
  69. Fleming L, Murray C, Bansal S, Hashimoto H, Bisgaard A, Bush A, et al (2015). The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015; 46:1322-1333.
    View at Publisher | View at Google Scholar
  70. Abul MH, Phipatanakul W. Severe asthma in children: evaluation and management. Allergol Int 2019; 68(2):150-157.
    View at Publisher | View at Google Scholar
  71. Fitzpatrick AM, Teague WG (2011). Progressive airflow limitation is a feature of children with severe asthma. J Allergy Clin Allergy Immunol 2011; 127:282-284.
    View at Publisher | View at Google Scholar
  72. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF (2014). The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014; 69:805-810.
    View at Publisher | View at Google Scholar
  73. Tagiyeva N, Devereux G, Fielding S, Turner S, Douglas G (2016). Outcomes of childhood asthma and wheezy bronchitis. A 50-year cohort study. Am J Respir Crit Care Med 2016; 193:23-30.
    View at Publisher | View at Google Scholar
  74. Buis DS, Watlers HE, Burgess JA, Perret JL, Buis MQ, Bowatte G, et al (2018). Childhood respiratory risk factor profile and middle-age lung function: a prospective cohort study from the first to the sixth decade. Ann Thorac Soc 2018; 15:1057-1066.
    View at Publisher | View at Google Scholar
  75. Barsky EE, Giancola LM, Baxi SN, Gaffin JM. A practical approach to severe asthma in children. Ann Am Thorac Soc 2017.
    View at Publisher | View at Google Scholar
  76. Custovic A., Martinez F.D. (2020). The Epidemiology of Severe Childhood Asthma. Springer Cham.
    View at Publisher | View at Google Scholar
  77. Forno E., Saglani S (2020). (eds) Severe Asthma in Children and Adolescents. Springer Nature Switzerland AG 2020.
    View at Publisher | View at Google Scholar
  78. Arasi S, Porcaro F, Cutrera R, Fiocchi AG (2019). Severe asthma and allergy: A pediatric perspective. Front Pediatr 2019; 7:28.
    View at Publisher | View at Google Scholar
  79. Lasmar LM, Carmagos PA, Ordones AB, Gasper GR, Campos EG, Ribiero GA (2007). Prevalence of allergic rhinitis and its impact on the use of emergency care services in a group of children and adolescents with moderate to severe persistent asthma. J Pediatr 2007; 83:555-561.
    View at Publisher | View at Google Scholar
  80. Deliu M, Belgrave D, Simpson A, Murray CS, Kerry G, Custovic A (2014). Impact of rhinitis on asthma severity in school-age children. Allergy 2014; 69(11):1515-1521.
    View at Publisher | View at Google Scholar
  81. Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011; 25:205- 208.
    View at Publisher | View at Google Scholar
  82. Won HK, Kim YC, Kang MG, Park HK, Lee SE, Kim MH, et al (2018). Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationship with asthma onset. Ann Allergy Asthma Immunol 2018; 120:389-394.
    View at Publisher | View at Google Scholar
  83. Spergel JM, Paller AS (2003). Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:S118-S127.
    View at Publisher | View at Google Scholar
  84. Burgess JA, Dharmage SC, Byrnes G, Matheson MC, Gurrin LC, Wharton CL, et al (2008). Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age. J Allergy Clin Immunol 2008; 122:280-285.
    View at Publisher | View at Google Scholar
  85. Gibson PG, Henry R, Coughlon JJ (2003). Gastro-esophageal reflux treatment for asthma in adults and children. Gibson PG, editor. (2003). Chichester: John Wiley & Sons, Ltd.
    View at Publisher | View at Google Scholar
  86. Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, et al (2012). Writing Committee for the American Lung Association Clinical Research Centers. Lansaprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307:373-381.
    View at Publisher | View at Google Scholar
  87. Prasad B, Nyenhuis SM, Weaver TE (2014). Obstructive sleep apnea and asthma: association and treatment implication. Sleep Med Rev 2014; 18:165-171.
    View at Publisher | View at Google Scholar
  88. Trivedi M, El Mallah M, Bailey E, Kremer T, Rhein LM (2017). Pediatric obstructive sleep apnoea and asthma: clinical implications. Pediatr Ann 2017; 46(9):e332-e335.
    View at Publisher | View at Google Scholar
  89. Roberts G, Patel N, Levi-Schaffer F, Habibi P, Lack G (2003). Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Clin Immunol 2003; 112:168-174.
    View at Publisher | View at Google Scholar
  90. Wang R, Custovic A, Simpson A, Belgrave DC, Lowe LA, Murray CS (2013). Different association of BMI and body fat with asthma and lung function in children. Pediatr Pulmon 2013.
    View at Publisher | View at Google Scholar
  91. Lang JE, Bunnell HT, Hossain MJ, Wysocki T, Lima JJ, Finkel TH, et al (2018). Being overweight or obese and the development of asthma. Pediatrics 2018; 142(6):e20182119.
    View at Publisher | View at Google Scholar
  92. Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedon JC, et al (2011). Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011; 127(3):749.
    View at Publisher | View at Google Scholar
  93. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, More WC, et al (2018). Baseline features of Severe Asthma Research Program (SARP III) cohort differences with age. J Allergy Clin Immunol Pract 2018; 6:545-554.e4.
    View at Publisher | View at Google Scholar
  94. Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG (2006). National Institutes of Health/National Heart, Lung, Blood Institute Severe Asthma Research Program. Features of severe asthma in school-age children. J Allergy Clin Immunol 2006; 118(6):1218-1225.
    View at Publisher | View at Google Scholar
  95. Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca MA, Marseglia GL, Ciprandi G (2018). Asthma endotypes and biomarkers of childhood asthma. Pediatr Allergy Immunol Pulmon 2018; 31:2.
    View at Publisher | View at Google Scholar
  96. Petsky HL, Kew KM, Chang AB (2016). Exhaled nitric oxide levels to guide treatment for school children with asthma. Cochrane Database Syst Rev 2016; 112:CD011439.
    View at Publisher | View at Google Scholar
  97. Moschino L, Zanconato S, Bozzetto S, Baraldi E, Carraro S (2015). Childhood asthma biomarkers: present and future steps. Pediatr Respir Rev 2015; 16(4):205-212.
    View at Publisher | View at Google Scholar
  98. Syabbalo N (2021). Biologics for the treatment of severe uncontrolled asthma. Asploro J Biomed Clin Case Report 2021; 4(1):60-69.
    View at Publisher | View at Google Scholar
  99. Marseglia GL, Licari A, Tosca MA, Cipranoli G. (2020) Biologics to treat severe asthma in children and adolescents: a practical update. Ped Allergy Immunol Pulmon; 33:4.
    View at Publisher | View at Google Scholar
  100. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. (2011) Randomized trial of omalizumab (anti-IgE) for asthma in an inner-city children. N Engl J Med; 364:1005-1015.
    View at Publisher | View at Google Scholar
  101. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derette J, et al. (2013) Add-on omalizumab in children with severe allergic asthma. 1-year real life survey. Eur Respir J; 42:1224-1233.
    View at Publisher | View at Google Scholar
  102. Bel EH, Wenzel SE, Thomson PJ, Prazma CM, Keene ON, Yancey SW, et al. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med; 371:1189-1197.
    View at Publisher | View at Google Scholar
  103. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med; 371:1198-1207.
    View at Publisher | View at Google Scholar
  104. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicenter, placebo-controlled phase 3 trial. Lancet; 388:2115-2127.
    View at Publisher | View at Google Scholar
  105. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. (2016) Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet; 388:2128-2141.
    View at Publisher | View at Google Scholar
  106. Castro M, Corren J, Pavord IB, Maspero J, Wenzel S, Rabe KF, et al. (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med; 378:2486-2496.
    View at Publisher | View at Google Scholar
  107. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med; 378:2475-2485.
    View at Publisher | View at Google Scholar
  108. Chipps BE, Lanier B, Milgrom H, Deschidre A, Hedin G, Szefler SJ, Kattan M, et al. (2017) Omalizumab in children with uncontrolled allergic asthma: review of clinical trials and real-world experience. J Allergy Clin Immunol; 139(5):1431-1444.
    View at Publisher | View at Google Scholar
  109. Henriksen DP, Bodtger U, Sidenius K, Maltback N, Pedersen L, et al. (2020) Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol; 16:49.
    View at Publisher | View at Google Scholar
  110. Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J. (2019) Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol; 144(5):1336-1342.e7.
    View at Publisher | View at Google Scholar
  111. Agache I, Rocha C, Beltran J, Song Y, Posso M, Sola I, Alonso-Coello P, Akdis, C, Akdis M, Canonica GW, Casale T, et al (2020). Efficacy and safety of treatment with biological (benralizumab, dupilumab and omalizumab) for severe allergic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biological in severe asthma. Allergy 2020.
    View at Publisher | View at Google Scholar
  112. Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL. Biological therapies in children and adolescents with severe uncontrolled asthma: A practical review. Biologics Targets Ther 2012; 2021(15):133-142.
    View at Publisher | View at Google Scholar
  113. Rathinam KK, Abraham JJ, Vijayakumar TM. Dupilumab in the treatment of moderate to severe asthma: an evidence-based review. Curr Ther Res Clin Exp 2019; 91:45-51.
    View at Publisher | View at Google Scholar
  114. Bacharier LB, Masepero JF, Katalaris CH, Fiocchi AG, Gagnon G, de Mir, Jain N, Sher LD, et al (2012). Dupilumab efficacy and safety in children with uncontrolled, moderate-to-severe asthma. The phase 3 VOYAGE study. Am J Respir Crit Care Med; 203: A1204.
    View at Publisher | View at Google Scholar
  115. Licari A, Castagnoli R, De Filippo M, Foiadelli T, Tosca MA, Marseglia GL, Ciprandi G (2020). Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opin Bio Ther 2020; 20(6):609-619.
    View at Publisher | View at Google Scholar
  116. Pfaar O, Gehrt F, Li H, Rudhart SA, Nastev A, Stuck BA, Hoch S (2021). Anti-IgE: A treatment option in allergic rhinitis? Allergol Select ; 5:119-127.
    View at Publisher | View at Google Scholar
  117. Bachert C, Battacharyya N, Desrosier M, Khan AH (2021). Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021; 14:127-134.
    View at Publisher | View at Google Scholar
  118. Casale TB (2017). Biologics and biomarkers for asthma, urticaria, and nasal polyps. J Allergy Clin Immunol 2017.
    View at Publisher | View at Google Scholar
  119. hNEWS: FDA approves asthma indication for dupixent-dupilumab
    View at Publisher | View at Google Scholar
  120. U.S. Food & Drug Administration. FDA approves first treatment or chronic rhinosinusitis with nasal polyps, June 26, 2019. Accessed July 24, 2019.
    View at Publisher | View at Google Scholar
  121. Sanofi. Sanofi and Regeneron announces FDA approval of Dupixent (dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis (media release). 2017. Accessed o2 May 2017.
    View at Publisher | View at Google Scholar
  122. FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis. Accesses September 14, 2020.
    View at Publisher | View at Google Scholar
  123. Hirano I, Delton ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 2020; 158(1):111-122.
    View at Publisher | View at Google Scholar
  124. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 2019; https://doi.org/10.111/cea.13491.
    View at Publisher | View at Google Scholar
  125. Satre J, Davila I. (2018). Dupilumab: A new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018; 28(3):139-150.
    View at Publisher | View at Google Scholar
  126. yabbalo N. Targeting alarmin cytokines in the treatment of asthma. J Pulm Med 2020; 4:5. Editorial.
    View at Publisher | View at Google Scholar
  127. Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracianoi R, Vatrella A. (2021). Tezepelumab: A potential new biological therapy for severe refractory asthma. Int J Mol Sci 2021; 22(9):4369.
    View at Publisher | View at Google Scholar
  128. Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, Vandenberghe I, Pauwels K, et al. (2017). Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun 2017; 8:14937.
    View at Publisher | View at Google Scholar
  129. Menziew-Gow A, Corren J, Bourdin A, Chupp G, Isreal E, Wechsler ME, Brightling CE, Griffiths T, et al. (2012). Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2012; 384(19):1800-1809.
    View at Publisher | View at Google Scholar
  130. Menziew-Gow A, Wechsler M, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res 2020; 21:268.
    View at Publisher | View at Google Scholar
  131. AstraZeneca. Tezepelumab granted Breakthrough Therapy Designation by US FDA. Accessed 5 Mar 2020.
    View at Publisher | View at Google Scholar
  132. Huang WL. (2018). The treatment of asthma based on traditional Chinse medicine and homeopathy. J Pediat Infants 2018; 1:1.
    View at Publisher | View at Google Scholar
  133. Reller, Paul L (2017). Asthma and COPD. 25 03 2018.
    View at Publisher | View at Google Scholar
  134. OuYang B, Gu Z (1996). Essentials of Traditional Chinese Medicine. Shandong Science and Technology Press.
    View at Publisher | View at Google Scholar
  135. Capra F (2013). Otao da fisica. Editora Cultrix.
    View at Publisher | View at Google Scholar
  136. Li X-M. (2007). Traditional Chinese herbal remedies for asthma and food allergy. J Allergy Clin Immunol 2007; 120(1):25-31.
    View at Publisher | View at Google Scholar
  137. Wang W, Yao Q, Tang F, Cui J, Dong J, Wei Y. Active ingredients from Chinese plants as therapeutic strategies for asthma: Overview and challenges. Biomed Pharmacother 2021; 137:111383.
    View at Publisher | View at Google Scholar
  138. Athari SS. Targeting cell signaling in allergic asthma. Signal Transduction and Targeted Therapy 2019; 4:45.
    View at Publisher | View at Google Scholar

Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.

img

Virginia E. Koenig

Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.

img

Delcio G Silva Junior

Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.

img

Ziemlé Clément Méda

Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.

img

Mina Sherif Soliman Georgy

We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.

img

Layla Shojaie

The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.

img

Sing-yung Wu

Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.

img

Orlando Villarreal

Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.

img

Katarzyna Byczkowska

Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.

img

Anthony Kodzo-Grey Venyo

Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.

img

Pedro Marques Gomes

Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.

img

Bernard Terkimbi Utoo

This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.

img

Prof Sherif W Mansour

Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.

img

Hao Jiang

As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.

img

Dr Shiming Tang

Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.

img

Raed Mualem

International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.

img

Andreas Filippaios

Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.

img

Dr Suramya Dhamija

Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.

img

Bruno Chauffert

I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!

img

Baheci Selen

"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".

img

Jesus Simal-Gandara

I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.

img

Douglas Miyazaki

We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.

img

Dr Griffith

I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.

img

Dr Tong Ming Liu

I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.

img

Husain Taha Radhi

I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.

img

S Munshi

Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.

img

Tania Munoz

“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.

img

George Varvatsoulias

Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.

img

Rui Tao

Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.

img

Khurram Arshad

Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.

img

Gomez Barriga Maria Dolores

The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.

img

Lin Shaw Chin

Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.

img

Maria Dolores Gomez Barriga